Guilin Pharmaceutical Co., Ltd was established in June 2001, with five enterprises as its shareholders including Guilin Pharmaceutical Corp., Ltd., Guilin Tianhe Pharmaceutical Co., Ltd, Shanghai Guojia Bio-technology Engineer Research Co., Ltd., Guilin Shenglongtang Bio-pharmaceutical Co., Ltd, and Guilin New and High Technology Industrial Development Corp.Guilin Pharmaceutical Corp., Ltd. owns 94.475% of the company’s shares. Its predecessor was Guilin Pharmaceutical Factory, which was a manufacturing enterprise for general medicine merged from itself and Shanghai Tangshiyi Pharmaceutical Factory moved to Guangxi Zhuang Autonomous Region. At present, it has a history of 98 years. In the later half year of 2003, the enterprise had undergone a reform, in which Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was introduced in as a strategic cooperative partner and owns its 60% shares after the reform. Guilin Pharmaceutical Co., Ltd is now an indirect shareholding subsidiary company of Shanghai Fosun Corporation.

The company’s products are complete in preparation types and diversified in varieties, it now has nearly 200 varieties in tablets, capsules, biological agents, chemosynthesis, injections, powder injection, etc, and all of its production lines have passed GMP certifications. Since the 1960s to now, it has been the largest pharmaceutical manufacturing enterprise in Guangxi Zhuang Autonomous Region all along, and has been listed as one of the key pharmaceutical enterprises of the state by China Pharmaceutical Industrial Association and China National Pharmaceutical Industrial Co., Ltd. Artesunate, a hi-tech product developed by the company with independent intellectual property rights has been approved as Class I new medicine by the Ministry of Health in 1987 with a patent for product invention, and in December 2005 , it passed the supplier pre-qualification of WHO. The combination therapy of Artesunate plus Amodiaqiune is recommended by some authoritative organizations such as Global Roll Back Malaria Committee and WHO, and has obtained WHO and GMP certifications. Production lines for Bumetanide , Levamisol, Levamisole Phosphate also have passed the FDA quality verifications of the US.

Having experienced a century of pioneering and progressing, Guilin Pharmaceutical Co.,Ltd has acquired good quality control systems and technical research and development abilities. Its distribution network covers all parts of the country. A number of its products are exported to more than 50 countries in Europe, America, Africa and Southeast Asia.

Depended on its hi-tech products, Guilin Pharmaceutical Co., Ltd. will adhere to the tenet of “Constantly progressing for your health” forever and endeavor to create an international brand of Chinese nation. With the spirit, courage and wisdom, through vigorous reform and bold deploitation, Guilin Pharmaceutical Co.,Ltd people will seize opportunities, face challenge and create a bright future.

□ Shanghai Tangshiyi pharmaceutical works was migrated into Guilin to merge with Guilin pharmaceutical works and found the Guilin Pharmaceutical Works in 1960.

□ Since Artesunate was successfully invented in 1987, it has possessed the No.1 certificate of class one new drug in P.R. of China.

□ As a joint venture company, SGM held by Guilin Pharmaceutical Works was established in Australia in 1989 with Levamisole as its main products.

□ Unique product Bumetanide passed the certification of US FDA in 1995.

□   Levamisole Hyrochloride passed the certification of US FDA in 1998.

□ Levamisole Phosphate passed the certification of US FDA in 2000.

□ Incorporating state mid-class Guilin No.2 Pharmaceutical Works was designated for production of power injection, injection, transfusion and raw material in Guangxi in December 2000.

□  Guilin Pharmaceutical Co., Ltd. held by Guilin Pharmaceutical Works was founded in 2001.

□  Artesunate was confirmed as an essential drug by WHO in the List of Essential Drugs of WHO in 2001.

□   Artesunate tablet passed the GMP audit of WHO in December 2002.

□  Guilin pharmaceutical works changed the name as “Guilin pharmaceutical Corp., Ltd ” in November 2003.

□   Guilin pharmaceutical Corp., Ltd signed a cooperation agreement with Shanghai Fosun Industrial Co., Ltd. in December 2003.

□  All production lines in company passed the GMP certification of P.R. China in June 2004.
□  Artesunate and its tablets passed the GMP audit of WHO in November 2004.

□   Artesunate tablets passed the pre-qualification of WHO in December 2005.

□  Amodiaquine Hydrochloride raw material and tablets passed the GMP authentication of WHO on February 28th 2006.